1211591-88-6 Usage
General Description
5-(trifluoromethyl)pyridazin-3-amine is a chemical compound with the formula C6H4F3N3. It belongs to the group of pyridazine derivatives, which are heterocyclic aromatic compounds. The presence of a trifluoromethyl group in the molecule makes it highly electronegative and has potential applications in pharmaceutical and agrochemical industries. This chemical may have diverse biological activities and has been explored for its potential as a building block in drug discovery and development. Additionally, it may also have applications in the field of material sciences and chemical synthesis due to its unique structure and reactivity. Further research is needed to fully understand the potential uses and properties of 5-(trifluoromethyl)pyridazin-3-amine.
Check Digit Verification of cas no
The CAS Registry Mumber 1211591-88-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,1,5,9 and 1 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1211591-88:
(9*1)+(8*2)+(7*1)+(6*1)+(5*5)+(4*9)+(3*1)+(2*8)+(1*8)=126
126 % 10 = 6
So 1211591-88-6 is a valid CAS Registry Number.
1211591-88-6Relevant articles and documents
COMPOUNDS USEFUL AS CSF1 MODULATORS
-
, (2016/04/26)
This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.
IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS
-
Page/Page column 29-30, (2010/08/08)
The invention encompasses imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.
